Operating out of a single office in Manhattan, Patterson Belknap elicits resounding praise from a vocal contingent of peers and clients, the likes of which are usually reserved for a national firm. “We think very highly of them,” opines one peer, summing up the general consensus. “They are not showy or flashy, they are just solid all across the board. We could use more like them.” A client extrapolates on the firm’s overall approach through a glowing accolade:
“They bring a potent combination of transactional and litigation expertise to the table to help clients achieve their objectives. Building on their knowledge of deal documents and judicial decisions, they are great strategists and excellent writers. They tell their client candidly when it has a weak position, rather than engaging in undue optimism.” The firm’s practice offering covers a diverse spectrum, spanning commercial matters, white-collar crime, antitrust, intellectual property, securities and false advertising claims, an area in which the firm is said to be one of the few major players. The firm’s hybrid model also affords it the freedom to take on cases in the plaintiff and defense roles. Patterson Belknap has also made headlines as of late for matters involving a more novel nature.
The firm, and namely Barbara Mullin, has been at the forefront of patent litigation as of late, with a series of Hatch-Waxman engagements for Janssen Pharmaceuticals, on which Mullin was lead trial counsel. She scored big for this client in a set of three consolidated actions against Mylan and is currently leading other cases against several other generic drug manufacturers.
Peter Tomlinson led a team that secured a significant victory on behalf of the Baldwin County Bridge Company when a judge granted injunctive relief against the Director of the Alabama Department of Transportation due to alleged bad-faith conduct on the Director’s part. Josh Goldberg represents Johnson & Johnson and its subsidiary Ethicon in a multi-billion-dollar litigation concerning Johnson & Johnson’s acquisition of the robotic-assisted surgical device manufacturer Auris Health. The allegations, filed by the entity representing former shareholders of the acquired company, took issue with the contingency payments that were to be made if certain FDA clearance and sales milestones were hit. Said milestones were not hit. The case proceeded to trial in January 2024. Geoffrey Potter leads the charge on an anti-counterfeiting crusade for Gilead, taking to task over 100 defendants, including pharmaceutical distributors and pharmacies, who are alleged to be part of an international counterfeiting ring that trafficked counterfeits of Gilead-branded HIV medication throughout the US, putting patients at risk. The counterfeits included bottles of Gilead-branded HIV medication that actually contained entirely different medication inside, such as high-dose antipsychotics. The counterfeiting ring also trafficked Gilead-branded bottles with counterfeit patient instructions and counterfeit chain-of-custody documentation that fraudulently claimed that the bottles were sold through authorized channels. Patterson Belknap is also one of the few New York firms to have cornered the market on the false advertising niche, primarily through Steve Zalesin, a universally lauded partner in this capacity. Zalesin represents household names such as Johnson & Johnson, Coca-Cola and Hershey in numerous actions concerning a multitude of products.
